Publications and Presentations

Multi-Parameter Optimisation Review Article

Multi-Parameter Optimisation Review Article

M. D. Segall, Curr. Pharm. Des., 2012, 18(9) pp. 1292-1310
DOI: 10.2174/138161212799436430

In this multi-parameter optimisation review, we survey the range of methods used for MPO in drug discovery, compare their strengths and weaknesses and present some example applications.


A successful, efficacious and safe drug must have a balance of properties, including potency against its intended target, appropriate absorption, distribution, metabolism, and elimination (ADME) properties and an acceptable safety profile. Achieving this balance of, often conflicting, requirements is a major challenge in drug discovery. Approaches to simultaneously optimizing many factors in a design are broadly described under the term ‘multi-parameter optimization’ (MPO).

In this review, we will describe how MPO can be applied to efficiently design and select high quality compounds and describe the range of methods that have been employed in drug discovery, including; simple ‘rules of thumb’ such as Lipinski’s rule; desirability functions; Pareto optimization; and probabilistic approaches that take into consideration the uncertainty in all drug discovery data due to predictive error and experimental variability. We will explore how these methods have been applied to predicted and experimental data to reduce attrition and improve the productivity of the drug discovery process.

You can read a preprint of this multi-parameter optimisation review as a PDF via the button below. Alternatively, visit the journal webpage to view the final published version. To find out more about multi-parameter optimisation, watch our more recent webinar on multi-parameter optimisation in practise.


Discover StarDrop™

With its comprehensive suite of integrated software, StarDrop™ delivers best-in-class in silico technologies within a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through predictive modelling to decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the drug optimisation and discovery process.